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Introduction 
Primary sclerosing cholangitis (PSC) is a chronic  bile duct disease with an estimated prevalence in the 
range of 1 to 16 per 100 000 with significant regional differences across Europe. The prevalence of PSC is 
increased in patients with ulcerative colitis and estimated in the range of 1-5% (1) MRI studies have 
showed that the prevalence of imaging changes compatible with PSC in ulcerative colitis is almost 4-fold 
higher than that detected based on clinical assessments (2). PSC is more common in men (comprising 
60-70% of the patients) and most patients present with pancolitis often with a right-sided predominance 
(3-5). A major challenge in the clinical management of the patients is a highly increased and 
unpredictable risk of biliary and colonic malignancies. 
The diagnosis of PSC is based on the combination of clinical, laboratory imaging and histological findings. 
Briefly, a diagnostic work-up for PSC should be performed in all patients with inflammatory bowel 
disease (IBD) and abnormal liver biochemistry tests, especially elevated ALP and gGT values, as well as 
non-IBD patients with elevated cholestatic liver enzymes not otherwise explained. A proposed algorithm 
for PSC diagnosis has already been proposed by prior European Association for the Study of the Liver 
(EASL) guidelines (6), and comprehensive discussion of issues unrelated to the use of endoscopy in PSC 
will not be addressed in the present Guideline. 
Endoscopic retrograde cholangio-pancreatography  (ERCP) plays a significant role in the handling of PSC 
due to its high accuracy, prognostic value as well as its sampling and therapeutic possibilities. However, 
ERCP must be integrated in well defined clinical algorithms together with less or non invasive imaging 
and biochemical tests. In particular, the widespread implementation of MR cholangiography (MRC) has 
led to an increasing restriction of the the use of ERCP to cases where the diagnosis is equivocal, or when 
sampling or endoscopic treatment are required.  
The aim of this evidence- and consensus-based Guidelines, commissioned by the European Society of 
Gastrointestinal Endoscopy (ESGE) and the EASL, is to provide practical advice on how to utilize ERCP 
and colonoscopy in PSC patients, in order to maximize its benefit and minimize its burden and adverse 
events. 
Methods 
 The ESGE and the EASL commissioned this Guideline and appointed panel representatives from both 
societies to participate in the project development. The Guideline development process included 
meetings and online discussions among members of the Guideline committee during January April 2015 
and July 2016. Key questions were prepared by the coordinating team. A systematic literature search in 
PubMed/MEDLINE and the Cochrane Library was conducted using at minimun the search terms 
“Primary Sclerosing Cholangitis” and “Endoscopy”, and “Colonoscopy” for the part related with the 
diagnosis and surveillance of IBD in PSC. Articles were first selected by title, their relevance was then 
assessed by reviewing full-text articles, and publications with content that was considered irrelevant 
were excluded. Aspects related to endoscopy in PSC patients after liver transplantation were omitted.  
Evidence tables were generated for each key question, summarizing the quality evidence of the 
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available studies. The entire process was performed according to the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) system (7). Draft proposals were presented to the 
entire group for general discussion and voting during a plenary meeting held in November 2015. 
In May 2016, a compiled manuscript prepared by L.A. and T.H.K. was sent to all group members. After 
revisions and agreement on a final version, the manuscript was submitted for peer review.  The revised 
manuscript was approved by all authors and the governing boards of ESGE and EASL and was 
subsequentely forwarded to Endoscopy and Journal of Hepatology for publication.  
Endoscopic diagnosis and surveillance of PSC  
Diagnosis of PSC 
1. ESGE/EASL recommend that, as the primary diagnostic modality for PSC, MRC should be preferred 
over ERCP (moderate quality evidence, strong recommendation). 
Although ERCP has been regarded as the standard of reference in diagnosing PSC, MRC is now 
recommended as first line non-invasive imaging method for patients with suspected PSC, offering 
comparable accuracy (except in in early stage of PSC restricted into intrahepatic bile ducts and the rare 
cases of contraindications to MRC) (8-12). A meta-analysis based on six studies using ERCP as a 
reference method concluded that MRC has high sensitivity and specificity (0.86 and 0.94, respectively) 
for the diagnosis of PSC (13). According to a decision model  comparing different approaches in the 
work-up of patients with suspected PSC (14), the strategy of initial MRC, followed by ERCP only in 
selected cases (e.g. ambiguous MRC findings), is the most cost-effective approach (14, 15).  
The ductographic features defining PSC are described below but a number of other diseases of the 
biliary tree may present similar features (table 1). The specificity of the cholangiographic features of PSC 
without the additional diagnostic clinical and biochemical clues is poor (16). 
Table 1: Classification of secondary sclerosing cholangitis and conditions that may mimic primary 
sclerosing cholangitis on cholangiography 
Infection Bacterial / parasitic cholangitis  
 Recurrent pyogenic cholangitis 
Immunodeficiency related 
(infections) 
Congenital immunodeficiency 
 Acquired immunodeficiency (e.g. HIV) 
 Combined immunodeficiencies 
 Angioimmunoblastic lymphadenopathy 
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Mechanic/toxic Cholelithiasis/choledocholithiasis 
 Surgical bile duct trauma 
 Intra-arterial chemotherapy 
 Drug-induced sclerosing cholangitis 
Ischaemic Vascular trauma 
 Hepatic allograft arterial insufficiency 
 Paroxysmal nocturnal haemoglobinuria 
Other pancreaticobiliary 
disease 
Cystic fibrosis  
 Sclerosing cholangitis of critical illness 
 ABCB4 associated cholangiopathy 
 Chronic pancreatitis 
Systemic inflammatory 
diseases 
IgG4-associated systemic disease 
 Hypereosinophilic syndrome 
 Sarcoidosis 
 Graft-versus-host disease 
Potentially mimicking on 
cholangiography 
Langerhans cell histiocytosis  
 Systemic mastocytosis 
 Caroli’s disease 
 Congenital hepatic fibrosis 
 Other types of ductal plate abnormalities 
 Hodgkin’s disease 
 Cholangitis glandularis proliferans 
 Neoplastic/metastatic disease 
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 Amyloidosis 
 Hepatic allograft rejection 
 
Of note, the visualization of the distal common bile duct and the peripheral intrahepatic ducts is still 
suboptimal using MRC (10, 12). One study has suggested that a numerical score calculated based on 
three-dimensional MRC may predict progression of bile duct changes but the study lacked ERCP 
reference (17). A diagnostic MRC, because of its very high specificity for the diagnosis of PSC when 
diagnostic clinical and biochemical clues are present, obviates a confirmatory ERCP unless therapeutic 
procedures or ductal sampling are indicated (13, 18).  
2. ESGE/EASL suggest that ERCP can be considered if MRC and liver biopsy is equivocal or 
contraindicated in patients with persisting clinical suspicion of PSC. The risks of ERCP have to be 
weighed against the potential benefit with regard to surveillance and treatment recommendations 
(low quality evidence, weak  recommendation). 
Whether or not to perform ERCP in patients with normal high–quality MRC depends on the level of 
clinical suspicion for PSC and impact of the diagnosis on patients management and prognosis. ERCP is 
regarded unnecessary in patients with a low level of clinical suspicion, but it could be considered in 
patients with intermediate or high level of clinical suspicion as suggested by a meta-analysis of MRC 
diagnostic performance (13). However, this meta-analysis included only studies performed prior to 
2007. The continuous improvement in MRC quality due to use of higher magnetic fields, as exemplified 
by the ability to visualize third- and fourth-order intrahepatic ducts as well as the availability of 3-
dimensional image acquisition, is likely to further decrease the probability of abnormal ERCP in patients 
with normal MRC. In addition, as detailed reports including clinical, biochemical and histological 
characteristics and outcome of these patients with negative MRC but positive ERCP are lacking, the 
clinical benefit of ERCP can be questioned in this setting. If high-quality MRC images are not available or 
in equivocal cases, it is reasonable to consider patient referral to centers with known technical expertise 
with MRC as a first step(19) , followed by liver biopsy. If high-quality MRC images and liver biopsy  still 
cannot definitely exclude or confirm the presence of PSC, ERCP can be considered in patients with 
persisting clinical suspicion for the diagnosis to take advantage of the filling pressure obtained by the 
balloon occlusion, and slight superiority as to visualization of the extrahepatic bile ducts.   
Ductographic criteria for PSC 
The first ERCP criteria for ductographic changes in PSC were published in 1984 by Li-Yeng (20). Typical 
changes seen in PSC consist of minor irregularities of duct contour and local narrowing with prestenotic 
dilatation (type I), threadlike narrowings alternating with normal caliber of bile ducts or slight dilatation 
(type II), multiple strictures with saccular dilatations (type III), and the most advanced changes 
consisting of advanced ductal narrowing with resultant lack of filling of the peripheral ducts (type IV). 
The classification has later been modified by Majojie et al (21) and Ponsioen et al (22, 23). The 
classification of Ponsioen et al (23) has been validated and shown to correlate with patient prognosis 
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(Table 2). Another type of classification is based on evaluation of the grade, length, and extent of 
strictures, the degree of bile duct dilatation, and the distribution of lesions (24). None of the 
ductographic criteria published are specific for PSC and the findings must be interpreted in the context 
of patient demographics and the clinical context.  Review by teams with an expertise in complex biliary 
disease is often useful, as multiple secondary causes of sclerosing cholangitis must be considered (25) 
(Table 3). 
Table 2. Amsterdam classification of cholangiographic changes in PSC (23) 
Type Intrahepatic Extrahepatic 
0 No visible abnormalities No visible abnormalities 
I Multiple caliber changes; minimal dilatation Slight irregularities of duct contour; no stricture 
II Multiple strictures; saccular dilatations, 
decreased arborization 
Segmental strictures 
III Only central branches filled despite 
adequate filling pressure; severe pruining 
Strictures of almost entire length of duct 
IV - Extremely irregular margins; diverticulum like 
outpoutchings 
 
Table 3 : Characteristic cholangiographic features in primary sclerosing cholangitis (PSC) and other 
ductal diseases 
Diagnosis Main Cholangiographic features 
PSC Multifocal intra- and extra-hepatic bile duct strictures (“beaded” appearance), 
slight biliary dilatation, diverticular  outpouchings, pruned-tree appearance at 
chronic stage 
Ascending cholangitis Multiple intrahepatic bile duct strictures, stones, biliary abscesses  
Ischaemic cholangitis Proximal intrahepatic bile duct strictures, bile duct necrosis, biliomas, 
abscesses, biliary cast 
Caustic cholangitis Localized intrahepatic bile duct strictures, irregularities of bile duct wall  
AIDS related cholangitis Stricture of the distal common bile duct, papillitis, acalculous cholecystitis 
IgG4 related cholangitis Multifocal central bile duct strictures, bile duct wall thickening with visible 
lumen, pancreatic abnormalities compatible with autoimmune pancreatitis 
Portal biliopathy Central and extrahepatic bile duct irregularities 
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Unusual cholangiographic features 
Some PSC patients may present with cystic dilatations of intrahepatic bile ducts simulating Caroli’s 
disease (10). Of note, the fusiform and small cystic dilatations of intrahepatic (mostly peripheral) bile 
ducts as observed in patients with congenital hepatic fibrosis and autosomal recessive polycystic kidney 
disease should not be misdiagnosed as PSC  (11). Another differential diagnosis is the peculiar 
cholangiographic phenotype of adult forms of ABCB4/MDR3 deficency which may be  characterized by 
large uni- or multifocal spindle-shaped intra-hepatic bile duct dilatations with or without apparent bile 
duct stenosis (12, 26). Diagnosis should be suspected on familial clustering of excessive gallstone disease 
and a history often with prior cholecystectomy at age < 40 years and associated intrahepatic cholestasis 
of pregnancy and is confirmed by ABCB4 genotyping. 
3.  ESGE/EASL do not suggest routine use of other endoscopic techniques (i.e.  EUS including IDUS, 
cholangioscopy, confocal endomicroscopy) than ERC for the diagnosis of PSC (weak recommendation, 
low quality evidence) 
In the diagnosis of PSC there is no established role for endoscopic techniques beyond ERCP,  e.g. brush 
cytology, ductal biopsy, cholangioscopy or confocal laser microscopy. In selected cases with suspected 
extrahepatic disease and inconclusive MRC findings, endoscopic ultrasound (including intraductal 
ultrasound, IDUS) and elastography may add information on common bile duct strictures, wall 
thickening and liver fibrosis stage (27-30).  
ERCP in established PSC 
4. ESGE/EASL suggest to define a dominant stricture (DS) at ERC as a stenosis with a diameter of ≤1.5 
mm of the common bile duct and/or ≤1.0 mm of a hepatic duct within 2 cm of the main hepatic 
confluence (weak recommendation, low quality evidence).  
Deciding on the clinical impact of a bile duct stricture may be challenging. The DS denomination arose 
alongside the term “major stricture” early in the history of endoscopic management of PSC (31). The 
“major” or “dominant” stricture terms were initially used more broadly pertaining to strictures of the 
common bile duct and right and left bifurcation of the hepatic ducts (extrahepatic PSC lesions), since 
these were found to be more prone to clinical events than intrahepatic strictures (31, 32). The precise 
definition of a DS was introduced by Stiehl et al. for the use in endoscopic studies as a severity measure 
in 2002 (33, 34), although is somewhat arbitrary set, depending on e.g. filling pressure.   A number of 
endoscopic studies both before and after 2002 do not apply the diameter criterion strictly when 
determining DS (35, 36), and focus on suspected clinical relevance. Determining the clinical significance 
and potential benefit from endoscopic interventions should therefore not be based on this definition 
alone and the decision for intervention rather considered a compound clinical decision. Multiple DS can 
be found in the same patient (12% in the study by Bjornsson et al) (34).   Of note, the ERCP definition of 
DS is usually considered as not applicable to MRC, in particular in the extrahepatic ducts, given the 
insufficient spatial resolution of MRC (37, 38) and the lack of hydrostatic pressure as provided by ERCP. 
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A  complete occlusion cholangiogram should generally be obtained if an ERCP is performed because it 
adds little risk to the ERCP, decreases variability, and may reveal that a DS suspected at MRC is indeed 
not a stricture (39).  
5.  ESGE/EASL suggest ERCP and ductal  sampling (brush cytology, endobiliary biopsies) should be 
considered in established PSC  in the case of (i) clinically relevant or worsening symptoms (jaundice, 
cholangitis, pruritus) (ii) rapid increase of cholestatic enzymes levels or (iii) new or progression of 
existing dominant strictures in ERC in the context of appropriate clinical findings (weak 
recommendation, low quality evidence).   
ERCP can be indicated in patients with a confirmed diagnosis of PSC when changes in clinical, laboratory 
and radiological findings occur during the course of the disease. The purpose is to make an assessment 
of the likelihood of the presence of biliary dysplasia as a risk factor for cholangiocarcinoma (CCA) and to 
determine biliary strictures amenable to intervention. 
a) Clinical events. 
In the early stage of PSC dominant biliary strictures are usually asymptomatic. Exacerbation of 
jaundice (not related to liver failure), episodes of fever and chills suggestive of cholangitis or 
worsening of pruritus are indications for ERCP for the treatment of dominant strictures and to 
perform ductal brush sampling to exclude malignancy (40, 41). Worsening pain in the right 
upper abdominal quadrant, fatigue and weight loss also need careful evaluation. 
b) Laboratory results. 
Serum laboratory tests are neither sensitive nor specific enough to evaluate PSC progression 
(41), but in case of rapid increase of serum bilirubin levels and/or cholestatic liver enzymes 
(serum alkaline phosphatase, serum gamma glutamyl transferase) ERCP is indicated (6), 
especially in patients with a diagnosis of clinically significant hilar or extrahepatic strictures on 
MRC. Elevation of serum CA19-9 in PSC patients has an unsatisfactory sensitivity (14%) and 
positive predictive value (67%) for the diagnosis of CCA (36, 41, 42), and is not helpful in 
selecting patients for ERCP. 
c) Progression/new onset clinically significant strictures on MRC. 
Progressive intra- or extra-hepatic bile duct dilatation on imaging studies (ultrasound or MRC) is 
an indication for ERCP with ductal sampling (6). A careful evaluation of new onset dominant 
strictures in PSC is recommended, due to the increased risk of CCA in this situation.   
In detail, a stricture disproportionately severe relative to others, concomitant biliary filling 
defects, marked biliary dilation [≥ 2 cm for the common bile duct, ≥1 cm for the right or left 
intrahepatic ducts, ≥ 5 mm for other intrahepatic ducts]) suggests CCA (43). Conversely, this risk 
was absent in patients without dominant strictures according to a 25 year experience (44).  
Abnormal cytological findings, such as suspicion of malignancy or aneuploid DNA findings need a 
close follow-up by ERCP with  repeated sampling, unless urgent liver transplantation is 
considered warranted. 
The utility of ERCP in handling DS was shown in a prospective study (45) on 171 PSC patients 
followed for 20 years: repeated endoscopic therapy was associated with a transplant free 
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survival of 81% at 5 years and 52% at 10 years after initial endoscopic therapy.  In this 
population,  a 6% CCA rate was found in patients with dominant strictures. 
6. EAGE/EASL suggest that, in patients with an established diagnosis of PSC, MRC should be 
considered before therapeutic ERCP (weak recommendation, low quality evidence).    
MRC may be useful to confirm the indication, exclude focal parenchymal changes and to give clinicians 
performing ERCP imaging based guidance to minimize the risk of complications. Regarding MRC in 
established PSC, a single retrospective centre study reported a 76% accuracy of MR with MRC in the 
diagnosis of CCA complicating PSC (43). For these reasons, patients  with an established diagnosis of PSC 
should have an MRC exam in his/her clinical records (13, 46).  
 
7. ESGE/EASL suggest performing endoscopic treatment with concomitant ductal sampling (brush 
cytology, endobiliary biopsies) of suspected significant stricture at MRC in PSC patients who present 
with symptoms likely to improve following endoscopic treatment (strong recommendation, low 
quality evidence). 
Selected series reporting on the endoscopic treatment in PSC patients are summarized in Table 4; none 
of these compared performance vs no performance of endoscopic treatment for DS. The benefits 
reported following DS dilation included short-term improvement of symptoms and of liver biochemical 
tests as well as a longer liver transplantation (LT)-free survival compared to that predicted using the 
Mayo clinical risk model. Similar findings have also been reported in several smaller case series (47-51).  
The main criticisms made to these studies are as follows: 
a) The Mayo clinical risk model was not designed to evaluate patients with DS; specifically, many 
patients underwent therapeutic ERCP because of elevated bilirubin, which is part of the Mayo 
risk score, and went down in most patients after the intervention. Hence, baseline Mayo risk 
score was not determined in a steady state situation; 
b) Serum tests for cholestasis may spontaneously fluctuate in patients with PSC complicated or not 
with a DS. Bjornsson et al reported in 125 PSC patients changes in s-ALP and s-bilirubin from 
baseline up to 12 months following ERCP. As patients with DS received no stricture dilation, the 
authors stated that “If our patients had been consequently dilated or stented the decrease in 
bilirubin and clinical features at follow-up would have been attributed to endoscopic therapy” 
(34). However, in that study, the variations reported in ALP and in total serum bilirubin after vs 
before ERCP were not significant, in contrast with various studies listed in Table 4 that used DS 
dilation/stenting. Also, it was not clear on what basis these patients were treated 
conservatively, while others did receive endoscopic therapy. 
Other limitations of most studies listed in Table 4 include a retrospective design, selection bias, 
reporting of results mixed for dilation ± stenting of DS as well as treatment with ursodeoxycholic acid 
started during follow-up in a minority of patients.  
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A critical issue is to weigh potential benefits vs. the certain risks of therapeutic ERCP in patients with no 
other therapeutic option except LT. Symptoms likely to improve following DS treatment generally 
include pruritus, pain, cholangitis and jaundice in patients with a significant (≥20%) increase in 
cholestasis while in patients with end-stage liver disease, only cholangitis is expected to improve. 
Finally, patients with advanced liver disease with cirrhosis may not benefit from endoscopic treatment. 
Ahrendt et al. reported no change in serum bilirubin at one year following endoscopic and/or 
percutaneous stricture dilation in 10 patients with cirrhosis and a baseline serum bilirubin ≥5 mg/dl (52). 
Death following endoscopic balloon dilation of DS has been reported in a patient with PSC and end-stage 
liver disease (53). Diagnostic ERCP was followed by deterioration of cholestasis in 7 of 8 vs. one of 7 
patients with more (Ludwig stage III or IV) vs. less (Ludwig stage I or II) advanced PSC at biopsy (54). 
Balloon dilation vs. stent therapy 
8. EASGE/EASL suggest that the choice between stenting and balloon dilation should be left at the 
endoscopist’s discretion (weak recommendation, low quality evidence). 
Results from selected series reporting on endoscopic treatment of dominant strictures in PSC are 
summarized in Table 4. Of note, (i) in the majority of studies that reported on balloon dilation for DS, 
stents were inserted in a minority of patients, (ii) a significant improvement in LT-free survival compared 
with the Mayo model has been reported only with balloon dilation and (iii) the perforation rate has been 
higher with stenting compared with balloon dilation. 
A single, retrospective, study compared balloon dilation vs. balloon dilation combined with stenting for 
DS in PSC patients (n=34 and n=37, respectively) (53). The “balloon dilation alone group” was treated by 
endoscopic means only while 23 (62%) patients in the “stenting” group underwent percutaneous 
treatment due to failed endoscopic access and/or DS dilation. Serum bilirubin similarly decreased in 
both groups of patients but more procedures and more complications were recorded in the stent vs. the 
balloon dilation group (median number of procedures per patient, 5.0 vs. 2.1, respectively; patients with 
complications, 54% vs. 15%, respectively). Complications included bile duct perforation in 7 (10%) 
patients, 5 of whom were in the stent group. However, conclusions are difficult to draw due to the 
different access routes used (percutaneous in 62% vs. 0 in the stent vs. balloon dilation group, 
respectively), a selection bias due to more severe stricture in the stent groupand the long stenting 
duration used (mean, 3 months) putting the patient at high risk for stent clogging and cholangitis. A  
short stenting duration (see recommendation 13) is currently the standard of care. 
The European multicenter randomized DILSTENT trial comparing single balloon dilatation versus short-
term stenting was prematurely stopped recently after a planned interim analysis. Preliminary results 
show no differences in outcome, but a significantly higher serious adverse event rate in the stent group, 
mainly consisting of PEP and suppurative cholangitis (ref. pending).  
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Role of sphincterotomy 
9. ESGE/EASL recommend weighing the anticipated benefits of biliary papilllotomy/sphincterotomy 
against its risks on a case-by-case basis (strong recommendation, moderate quality evidence). Biliary 
papillotomy/sphincterotomy should be considered especially after difficult cannulation (strong 
recommendation, low quality evidence).  
Biliary sphincterotomy was performed routinely as part of the endoscopic treatment of DS in some 
studies (53) while its use was restricted to specific cases such as stone extraction and difficulties in stent 
insertion in other studies. For example, in 32 PSC patients treated with stents for DS, sphincterotomy 
was performed in 12 (38%) patients (55) while in another study of DS dilation±stenting, sphincterotomy 
was performed in 63% of 63 patients (56). 
Generally, biliary sphincterotomy is not recommended as a routine procedure prior to biliary stenting 
because of the associated risks as demonstrated in RCTs (57). However, if cannulation is difficult, biliary 
sphincterotomy is advised, when considering that these patients are likely to require multiple 
procedures. Many endoscopists prefer a small sphinterotomy in PSC in order to avoid ascending 
cholangitis. 
Specifically in PSC, biliary sphincterotomy was independently associated with an increased risk of short-
term adverse events in two retrospective studies (odds ratios [OR] 4.7 and 5.0) (58, 59) while previous 
biliary papillotomy/sphincterotomy was protective for subsequent ERCPs (58); therefore experienced 
endoscopists perform biliary sphincterotomy in patients with difficult cannulation in whom ERCP is likely 
to be repeated during follow-up. 
Balloon dilation  
10. ESGE/EASL suggest selecting  the balloon calibre of up to the the maximum caliber of the ducts 
delimiting the stricture (weak recommendation, low quality evidence). 
11. ESGE/EASL suggest repeating dilation of relapsing DS if (i) the DS is regarded as the cause of 
recurrent symptoms (cholangitis, pruritus) or of significant increase in cholestasis and (ii) patient’s 
response to previous dilations has been satisfactory (weak recommendation, very low evidence). 
There are no comparative data on the optimal dilation scheme or balloon diameter for treating DS. In 
the largest prospective study (500 endoscopic balloon dilations in 96 patients), the authors performed 
stepwise DS dilation up to diameters of 8 mm and 6-8 mm in the common bile duct  and the hepatic 
ducts, respectively (60). Bile duct diameter upstream and downstream of the DS should be taken into 
account for selecting the balloon diameter to avoid dilating to more than the duct diameter. Balloon 
dilations are usually repeated at intervals of one to four weeks up to technical success, for an average of 
2-3 balloon dilations (33, 51, 60). Technical success has been defined as complete balloon inflation 
within the DS with no waist observed fluoroscopically followed by the unobstructed passage of contrast 
medium through the dilated biliary segment to the duodenum (51, 60). Using this technique, bile duct 
perforation was reported in 0.2% of DS dilations (1% of patients) (60). In contrast, another study that 
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used 4-12 mm in-diameter balloons for dilation reported dilation-related biliary perforations in 3.5% of 
procedures (56). 
Repeat balloon dilation during follow-up after initial treatment (usually consisting of several ERCPs) has 
been mentioned in some studies but no results of the repeat dilation in terms of clinical or biochemical 
improvement has been reported (33, 51).  
Stent therapy 
12. ESGE/EASL suggest selecting a single 10-Fr stent or two 7-Fr stents for, respectively, for DS in the 
extrahepatic ducts or hilar strictures extending into the left or right hepatic duct (final stent diameters 
in the case of stepwise stenting) (weak recommendation, very low quality evidence). 
In all large studies of endoscopic treatment for DS, plastic stents measuring 7 to 10-Fr in diameter were 
used, with no comparison of the results obtained with various stent diameters reported. Specifically, the 
Amsterdam group aimed at inserting a single 10-Fr stent, and if this was not possible at first attempt, it 
was preceded by 1-week stenting with a 7-Fr stent or insertion of a nasobiliary catheter (55, 61). The 
Mayo group used 7–10-Fr stents at the endoscopist’s discretion (53). The Indianapolis group did not 
mention the diameter of stents used (56). Two 7-Fr stents have typically been used in patients with 
multiple bilateral DS and in patients with a hilar stricture extending into the left or right hepatic duct in 
order to avoid temporary obstruction of the contralateral biliary system. In general, the stent caliber and 
length must be adapted to the specific biliary tree configuration.  
In other diseases, studies have shown that polyethylene stents provide better short-term (one-month) 
patency than Teflon models and that, at long-term, 10-Fr models provide longer biliary patency 
compared with thinner ones (11.5-Fr models do not provide longer patency) (57). 
With respect to balloon dilation prior to stenting, it is currently unclear whether a balloon dilation is 
beneficial before stent placement.  
Duration of stenting 
13. ESGE/EASL suggest that stents used for treating DS should be removed 1-2 weeks following 
insertion (weak recommendation, low quality evidence). 
No comparison of various stenting durations has been identified in studies reporting on stenting for DS. 
A short stenting duration is currently favored because stents tend to clog rapidly in PSC patients and 
similar efficacy results have been reported with short (1-2 weeks) vs. standard (8-12 weeks) stenting 
duration. Specifically, a retrospective study of short-term stenting (mean duration, 11 days) in 32 
symptomatic PSC patients with DS showed, at two months, a symptomatic improvement in 83% of the 
patients as well as a significant improvement of cholestasis tests; at one and three years, actuarial 
analysis showed that 80% and 60% of patients, respectively, would not require reintervention (55). Stent 
dysfunction was not reported in this study but two patients treated by stent removal developed hydrops 
of the gallbladder. The same group of authors had previously reported similar efficacy results with 3-
month stenting in 25 patients with symptomatic DS but, in that study, unscheduled stent exchange had 
to be performed on 32 occasions due to suspected stent clogging (cholangitis, n=23; jaundice, n=9) (62).  
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All studies mentioned focused on clinical and serum liver tests, not radiological data, to assess the short-
term effect of therapeutic ERCP (53, 55, 61, 62). Endoscopic treatment has been repeated in a sizeable 
proportion of patients: for example, with long median stenting periods (3 months), the median number 
of repeated ERCPs per patients ranged between 3 and 5 during follow-up periods of 29 and 22 months 
in two studies (53, 62) while following a short stenting period (mean, 11 days) repeat ERCP rates at one 
and three years after treatment were estimated at 20% and 40%, respectively (55). Other details about 
repeated treatments were not reported. 
In many centers, stents are removed during an esophagogastroduodenoscopy without biliary 
opacification in PSC patients. 
Table 4: Selected series reporting on endoscopic treatment of dominant strictures in primary 
sclerosing cholangitis  
First author, 
Year 
Study 
design 
N Intervention Outcomes Results 
1. Dilation ± stenting     
Gotthardt, 
2010 (extension of 
Stiehl 2002 study 
(33)) (60) 
Pro-
spective  
96 
(AP>2xUL
N) 
Balloon dilation (8 mm 
in CBD, 6-8 mm for 
IHBD), plus stent in 5 
patients with severe 
cholestasis and bacterial 
cholangitis 
Short-term 
improveme
nt in 
cholestasis; 
transplant-
free 
survival; 
complicatio
ns 
- At 2 weeks, 
mean bilirubin 
level 
significantly 
decreased (by 
56%) 
- Change in 
symptoms and 
LT-free survival - 
Comparison 
with Mayo 
model not 
reported (5-and 
10-year LT-free 
survival, 81% 
and 52%) 
- Overall 
complication 
rate, 3.8% 
 
Gluck, 2008 (35) Retro-
spective 
84, 
symptom-
matic 
patients 
Balloon dilation and 
stenting (70% and 51% 
of patients, 
respectively) 
LT-free 
survival 
- Higher 
proportion of 
patients alive 
with no LT at 3 
and 4 years than 
predicted using 
Mayo model (P 
< 0.05); at 1 and 
2 years similar 
survival 
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- Adverse events 
in 21 
therapeutic 
ERCPs (7.2% of 
291 procedures, 
25% of patients) 
Stiehl, 2002 (33) Pro-
spective  
52 
(AP>2xUL
N) 
Balloon dilation (8 mm 
in CBD, 6-8 mm for 
IHBD), plus stent in 5 
patients with severe 
cholestasis and bacterial 
cholangitis 
Bilirubin 
and liver 
enzymes 2 
weeks after 
dilation, 
symptoms, 
LT-free 
survival 
- At 2 weeks, 
significant 
decrease in liver 
enzymes and 
bilirubin  
- Improvement 
of jaundice in 
24/24 and of 
pruritus in 
12/13 patients 
- Longer LT-free 
survival than 
predicted using 
1992 Mayo 
model (P < 
0.0001) 
Baluyut, 
2001 (56) 
Retro-
spective 
56 with 
and  
7 without 
symptom
s 
Balloon dilation (4-12 
mm, N=61) 1x/year, 
with stent if no 
significant radiological 
improvement following 
dilation (N=33) 
LT-free 
survival, 
complicatio
n rate  
- Longer LT-free 
survival than 
predicted using 
1999 Mayo 
model (P=0.027) 
- 12% 
complications 
 
2. Stenting     
Ponsioen, 
1999 (55) 
Retro-
spective 
32 
symptom-
matic 
patients 
with 
successful  
stenting 
for DS 
One-week stenting (10 
Fr stent) with no 
balloon dilation 
Two-month 
symptomat
ic and 
biochemica
l 
improveme
nt, 
actuarial 
curve of 
reinterventi
on-free 
patients 
 
- Improvement 
of symptoms in 
83% 
- Significant 
decrease in 
bilirubin (44% 
had increased 
conjugated 
bilirubin at 
baseline) and 
cholestasis 
enzymes  
- 
Reintervention-
free patients 
(actuarial): 60% 
at 3 years 
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van Milligen de Wit, 
1996 (62) 
Retro-
spective 
25  
with 
symptom
s or 
progressi
on of 
serum 
tests for 
cholestasi
s 
Stenting for a median of 
3 months (plus 8-mm 
dilation in 3 patients) 
Change in 
symptoms 
and 
biochemica
l tests 
within 6 
months 
following 
stent 
insertion; 
Adverse 
vents 
- Improvement 
of symptoms in 
76%  
- Significant 
decrease in 
bilirubin (52% 
had increased 
bilirubin at 
baseline) and 
serum tests for 
cholestasis; 
- 32 episodes of 
cholangitis/jaun
dice related to 
stent clogging 
 
3. Dilation v. stenting     
Kaya, 
2001 (53) 
Retro-
spective 
71 
with 
symptom
s 
Balloon dilatation (4-8 
mm, N=34) vs balloon 
dilation with 3-4-month 
stenting (N=37). 
Intervention via PTBD in 
0/34 vs 23/37 patients 
in balloon vs stent 
group 
Biochemica
l course up 
to 24 
months 
- Both strategies 
improved liver 
biochemistry, 
fever resolved 
only in the 
dilatation 
without stent 
group. No 
additional 
benefit of 
stenting after 
balloon 
dilatation 
- More 
complications in 
stent vs dilation 
alone group 
(P=0.001) as 
well as in PTBD 
vs ERCP group 
(P<0.001) (no 
multivariate 
analysis) 
 
 
AP, alkaline phosphatases; DS, dominant stricture; ULN, upper limit of normal values; CBD, common bile 
duct ; IHBD, intrahepatic bile ducts ; UDCA, ursodeoxycholic acid ; LT, liver transplantation ; SAE, serious 
adverse events ; PTBD percutaneous transhepatic biliary drainage. 
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Complications of endoscopic therapy 
14. ESGE/EASL suggest that ERCP in PSC patients should be undertaken by experienced 
pancreaticobiliary endoscopists (strong recommendation, very low quality evidence). 
Several studies have evaluated the risk of complications in PSC patients undergoing ERCP (63-74). ERCP 
carries an increased risk for complications in the context of PSC, especially pancreatitis, cholangitis and 
extravasation of contrast, although not all the studies were documented such an increased risk in PSC 
(69, 74). In the systematic survey (75) of post-ERCP complications on various indications for ERCP 
including 21 prospective studies and 16,855 patients the number of total complications was 6.85% (CI 
6.46-7.24%). Pancreatitis occurred in 585 subjects (3.47%, CI 3.19-3.75%). In another large retrospective 
single center study (76) with 11,497 procedures over 12 years the total complication rate was 4.0 % and 
pancreatitis occurred in 3.6%. The overall risk of adverse events in patients with PSC has varied in 
different, much smaller, studies from 1.8 % to 18.4 % (63-74), which is higher than reported in other 
indications (75, 76).  
Retraction of the papilla and an altered, more difficult, position of the endoscope due to hypertrophy of 
the left liver lobe may be encountered during ERCP in PSC patients. Whether this actually influences 
cannulation success rates has not been investigated by specific studies. Cohort studies describing PSC 
patients provide only limited details on cannulation difficulties with failure rates of 0% to 6% (36, 44, 64-
66, 74, 77-80). Furthermore, there is likely a selection bias since most retrospective series describing the 
results of endoscopic treatment have the initiation of therapy as prerequisite, therefore potentially 
excluding cannulation failures.  
The largest series is the study by Ismail et al (71). In this retrospective review of 441 ERCP procedures 
over a three-year time period, primary cannulation success was 88.2%. Of note, in 137 patients (37.8%) 
a previous biliary sphincterotomy had been performed. Pancreatic sphincterotomy as an access 
technique was used in 11.8%  and freehand needle knife sphincterotomy in a further 2.5%. Primary 
failure rate was 0.5%. These figures suggest that cannulation in PSC patients may indeed be more 
difficult than in other types of patients.  
Post-ERCP pancreatitis  
15. ESGE/EASL recommends routine rectal administration of 100mg of diclofenac or indomethacin 
immediately before or after ERCP in all patients without contraindication. In addition to this, in the 
case of high risk for post-ERCP pancreatitis, the placement of a 5-Fr prophylactic pancreatic stent 
should be considered (strong recommendation, high quality evidence).  
Post ERCP-pancreatitis (PEP) is the most common and feared complication associated with ERCP. The 
risk for PEP in PSC vary from 1 to 7 %, although the diagnostic criteria vary between studies (81). 
Although the quality of the evidence is low, risk factors increasing the risk for PEP are probably not 
different in PSC patients from the general population: female sex (odds ratio [OR] 2.6, P= 0.015) and a 
guide wire in the pancreatic duct (OR 8.2, P<0.01). Native papilla increases whereas previous 
sphincterotomy decreases the risk (71), suggesting that preemptive EPT might be warranted in PSC 
patients where repeat procedures might be anticipated. This has however yet to be proven. 
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Prolonged papilla contact time as well as therapeutic procedures such as biliary brush cytology, 
sphincterotomy, stenting and dilatation are associated with increased risk of PEP. Precut biliary and 
pancreatic sphincterotomy is markedly associated with PEP (71), possibly reflecting the difficult 
cannulation and prolonged procedure time.  The recent Cochrane analysis comparing the contrast-
assisted technique with the guidewire-assisted cannulation technique showed that guidewire technique 
both increased the primary cannulation rate and reduced the risk of PEP, and it appears to be the most 
appropriate first-line cannulation technique (82). 
Rectal NSAIDs.  In its 2014 update to the Guideline on the prophylaxis of post-ERCP pancreatitis, the 
ESGE recommends routine rectal administration of 100mg of diclofenac or indomethacin immediately 
before or after ERCP in all patients undergoing ERCP without contraindication to NSAIDs (83). The 
recommendation was supported by the results of six meta-analyses published between 2009 and 2014 
that compared NSAIDs vs. placebo administration for prophylaxis of post-ERCP pancreatitis. These meta-
analyses concordantly showed the benefit of NSAIDs in preventing either mild or moderate/severe PEP. 
These results were further supported by subsequent meta-analyses (84, 85) and the cost-efficiency of 
this approach has been demonstrated (86). This recommendation applies to PSC patients. 
Pancreatic stenting:  The ESGE 2014 recommendation about prophylactic pancreatic stenting was 
supported by (i) three meta-analyses of RCTs that showed a significant reduction in the incidence and 
the severity of PEP when prophylactic pancreatic stenting was used and (ii) a study showing that 
pancreatic stent placement is cost-effective only in patients/procedures at high risk for post-ERCP 
pancreatitis.  
The following conditions relevant to PSC are considered to represent high risk for PEP: precut biliary 
sphincterotomy, pancreatic guidewire-assisted biliary cannulation, endoscopic balloon sphincteroplasty, 
pancreatic sphincterotomy, and presence of more than three of the following risk factors: female 
gender, previous pancreatitis, younger age, nondilated extrahepatic bile ducts, absence of chronic 
pancreatitis, normal serum bilirubin, cannulation attempts duration > 10 min, pancreatic guidewire 
passages > 1, pancreatic injection, failure to clear bile duct stones, intraductal ultrasound.  
16.ESGE/EASL  suggest routine administration of prophylactic antibiotics before ERCP in patients with 
PSC (strong recommendation, low quality evidence). 
Bacterial cholangitis and bacteriobilia are not an infrequent finding among patients with PSC. In studies 
evaluating the complications of ERCP in PSC the risk for cholangitis has varied from 0.2 to 8 % (63-74), 
depending among other items on the criteria used to define cholangitis. The use of prophylactic 
antibiotics markedly varies between studies in terms of prevalence, type of antibiotic and duration of of 
administration (from one oral dose before the procedure to one-week dosing afterwards). In a Cochrane 
meta-analysis (9 RCTs, 1573 patients), the prophylactic use of antibiotics was shown to prevent 
cholangitis (relative risk (RR) 0.54, 95% CI 0.33 to 0.91), septicemia (RR 0.35, 95% CI 0.11 to 1.11), 
bacteriemia (RR 0.50, 95% CI 0.33 to 0.78), and pancreatitis (RR 0.54, 95% CI 0.29 to 1.00). It was 
concluded that prophylactic antibiotics reduce bacteriemia and seem to prevent cholangitis and 
septicemia in patients undergoing elective ERCP (87). Our recommendation is in line with the ASGE 
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recommendation to prescribe antibiotic prophylaxis in procedures where drainage achieved at ERCP is 
incomplete or achieved with difficulty, such as PSC (88). Bile fluid sampling could be considered during 
ERCP, to guide antibiotic treatment in case cholangitis occurs despite the prophylaxis (89) 
Table 5.  Complications of ERCP in PSC patients.  
First author, 
year, country 
Study design Patients/ERCPs Complications, % 
 
   Total Pancreatitis Cholangitis 
Lee, 1995, USA 
(65) 
Retrospective  53/175 13.7  7 8 
van den Hazel, 
2000, The 
Netherlands 
(66) 
Retrospective 83/106 9 3 2 
Baluyut, 2001, 
USA (56) 
Retrospective 63/63 1.8  1.26  
 
0.6 
Stiehl 2002, 
Germany (64) 
Retrospective 106/ ERCP yearly, 
median 5 years  
9  5.2  3.3  
Enns, 2003, 
Canada (67) 
Retrospective 104 17  5  7.5  
Gluck, 
2008,USA (68) 
Retrospective 106/317 7.3  3.8  0.95 
Etzel, 2008, 
USA (74) 
Retrospective PSC:30/85 
Non-PSC:45/70 
12.9 
8.6 
2.4 
2.9 
5.9 
1.4  
Bangarulinga
m 
2009, USA (69) 
Retrospective PSC: 168 
Non-PSC: 981 
11  
8  
5 
4 
3.6  
0.2  
Alkhatib, 
2011, USA (70) 
Retrospective 75/185 8 5 1 
Ismail, 2012 
Finland (71) 
Retrospective 441/441 9 7 - 
Navaneethan 
2015, USA (72) 
Retrospective 294/697 4.3 1.2 2.4 
von Seth,2015, 
Sweden (73) 
Retrospective, 
national 
registry study 
PSC: 141/141 
Non-PSC: 8791 
18.4 
7.3 
7.8 
3.2 
 
7.1 
2.1 
 
PSC and cholangiocarcinoma 
17.  EASL/ESGE recommend that CCA should be suspected in any patient with worsening cholestasis, 
weight loss, raised serum CA19-9 and/or new or progressive DS, particularly with an associated 
enhancing mass lesion (strong recommendation, moderate quality evidence)  
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18. A raised serum CA19-9 may support the diagnosis of CCA, but has a poor specificity (weak 
recommendation, low quality evidence).  
PSC is associated with a markedly increased risk for CCA with a lifetime risk of 10%-20% (90, 91), or up to 
400-fold compared with the general population (92). CCA represents a common cause of death among 
PSC patients (93), whereby 27-50% of all CCAs are detected within one year of a PSC diagnosis (44, 94, 
95) depending on the indications for ERCP.  
CCA should be suspected in PSC patients experiencing rapid deterioration of liver function tests, 
increasing jaundice, weight loss and abdominal pain. However, the development of such a clinical trend 
may also suggest an advanced form of CCA. An observational study performed in the U.S. on 230 PSC 
patients affected by PSC, twenty-three of which had CCA, showed no major differences in the clinical 
features of the patients with or without CCA when the malignancy is at an earlier stage (43). 
Increased s-CA19-9 have been reported to indicate the development of CCA in PSC patients. Employing 
129 or 100 U/mL cut-off levels detected CCA with high sensitivity (nearly 80%) and specificity (nearly 
100%) (96), but only in advanced cases of CCA. These data are in contrast with other observations, which 
showed that one third of PSC patients with high CA19-9 levels did not have CCA.(97, 98) In a recent 
study performed on 433 PSC patients, 41 of whom had biliary malignancy, the use of FUT2/3 genotype-
dependent cut-off values for CA19-9 improved sensitivity and reduced the number of false positive 
results (99). In a study screening for biliary dysplasia using ERCP and brush cytology, serum CA19-9 had 
no prognostic value for biliary dysplasia or CCA (39). Currently, there are no definite radiologic features 
that indicate CCA in a PSC patient, although the detection of a DS by MRCP may be suggestive for CCA. 
However, 50% of PSC patients experience a DS and its absence does not rule out CCA. In a cohort of 230 
patients, US, CT and MRCP were found to have high specificity but low sensitivity (10-32%).(43)   
ERCP findings indicative of CCA 
DSs are frequent in PSC (60) and do not per se indicate development of a malignancy. In a large single 
center study, CCA was seen in 6/95 DSs (6%). In general it could be inferred that the chance of any DS of 
harbouring a CCA is around 5%. Most CCAs develop in perihilar region or in extrahepatic bile ducts, and 
are reachable with cytological  brush. In a large series of patients with CCA (100), 50% had perihilar CC 
(pCC), 42% had distal CC, and only 8% of the CCA’s were intrahepatic CCA. No specific imaging features 
have been found to differentiate benign strictures from malignant ones. Based on ERCP findings only it is 
not possible to exclude CCA from benign strictures caused by PSC, and the diagnosis requires always 
additional techniques such as biliary cytology or histology.  
19. ESGE/EASL recommend ductal sampling (brush cytology, endobiliary biopsies) as part of the initial 
investigation for the diagnosis and staging of suspected CCA in patients with PSC (strong 
recommendation, high quality evidence).  
20. ESGE/EASL suggest that fluorescence in situ hybridization (FISH) or equivalent chromosomal 
assessments are considered in patients with suspected CCA when brush cytology results are equivocal 
(weak recommendation, low quality evidence) 
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21 ESGE/EASL suggest that additional investigations such as cholangioscopy, endoscopic ultrasound 
and probe-based confocal laser endomicroscopy (pCLE) may be useful in selected cases (weak 
recommendation, low quality evidence).  
Brush cytology 
Bile duct brushing is the most common method for tissue sampling in patients with PSC for detecting 
inflammation, biliary dysplasia or CCA. In a recent meta-analysis (11 studies, 747 patients) (101), the 
pooled sensitivity, specificity, positive predictive value and negative predictive value of bile duct 
brushings for diagnosis of CCA in patients with PSC were 43% (95%CI, 35%-52%), 97% (95% CI, 95%-
98%), 78.2% (95% CI, 63.6%-86.7%), and 87.2% (95% CI, 85.4%-89.1%), respectively. The authors 
concluded that bile duct brushing is a simple and highly specific technique for detecting CCA in patients 
with PSC. However, the modest sensitivity from bile duct brushing precludes its utility as a diagnostic 
tool for early detection of CCA in patients with PSC. In a recent study of 261 mostly (81%) asymptomatic 
patients with PSC referred for their first ERC to confirm diagnosis and screen for biliary dysplasia with 
systematic bile duct brushings, 43% were found to have advanced disease, and malignant/suspicious 
cytology was present in 6.9% (39).  
Addition of FISH analysis of cytology specimens enhanced the sensitivity for detecting CCA in patients 
with PSC in several patient series (42, 43, 102, 103). The ideal methodology (e.g. FISH vs. digital image 
analysis [DIA] vs. flow-cytometri) and appropriate threshold values for markers assessed by each of 
these methodologies have not been robustly established and this makes meta-analysis of available data 
challenging (104). For this reason, chromosomal assessments can so far only be recommended in 
equivocal cases (104). As DNA technologies evolve, new markers are likely to emerge. 
Ductal biopsy  
Ductal biopsy has shown to improve the sensitivity, specificity and accuracy to diagnose CCA compared 
to brush cytology alone (105). Since the sampling area for ductal biopsies is limited, complementary 
biliary brushings should be considered in all patients. The sensitivity and specificity for the detection of 
CCA by ductal biopsy in published studies varies from 30-88%, and 97-100%, respectively (106). 
Combining brush cytology and biopsy has a sensitivity varying from 47-86% and specificity of 97-100%. A 
study (106) assessing the accuracy of triple modality: brush cytology, biopsy and FISH or their 
combination demonstrated that brush cytology alone had a sensitivity of 42%, specificity of 100%, 
positive predictive value of 100% and negative predictive value of 88%. Triple sample assessment 
modality markedly improved the overall sensitivity (82%), specificity (100%), positive predictive value 
(100%), and negative predictive value (87%). 
Cholangioscopy 
Peroral cholangioscopy (POCS) allows a direct visualization of extrahepatic bile duct strictures. The 
recent development of video-based systems offers  better image resolution and offers clearer views 
than fiberoptic cholangioscopy. Compared to ERC and tissue sampling POCS was shown to improve the 
diagnostic accuracy (107, 108) (109). However, these studies were not focused on CCA in PSC-patients.  
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Single-operator cholangioscopy (SpyGlass)  is gaining popularity, primarily for stone treatment and 
assessment of indeterminate strictures.  The utility in PSC was studied in a recent case series (110) with 
visual assessment and targeted biopsies of 64 strictures in 47 patients.  Only 1 of 3 patients with CCA  
were diagnosed by the ERCP procedure. It is likely that newer digital versions of this instrument (e.g. 
SpyGlass DS) will perform better, at least in terms of visual diagnostics.   
Other techniques 
Other techniques such as intraductal ultrasonography and confocal laser endomicroscopy have shown 
potential utility in the diagnosis of CCA in PSC, but are not established in routine clinical practice. 
Regular endoscopic ultrasonography with sampling of detectable masses or locoregional lymph nodes is 
advocated by some, but such sampling is also regarded as a contraindication to LT in some centers, thus 
any such sampling should be discussed locally.  
Table 6.  Detection of biliary malignancy in PSC with brush cytology (BC) 
First author, 
year 
Study design Intervention Participants Outcomes Results: Sens, 
Spec, PPV, NPV 
Ponsioen, 
1999, (111) 
Prospective ERC with BC 
from 
dominant 
strictures 
43 Detection of 
malignancy/CC 
60%, 89%, 59%, 
89% 
Lindberg, 2002, 
(112) 
Prospective BC + DNA 
flow 
cytometry 
from biliary 
strictures 
57 Detection of 
malignancy/CC 
71% ,100 %, NA, 
NA 
Siqueira, 2002, 
(113) 
Retrospective BC from bile 
ducts 
151 Detection of 
malignancy/C 
46.4%, 100%, 
NA,NA 
Lal, 2004, (114) Retrospective BC from bile 
ducts 
21 Detection of 
malignancy/CC 
67%,94%,NA,NA 
Furmanczyk, 
2005, (115) 
Retrospective BC from bile 
ducts 
51 Detection of 
malignancy/CC 
62.5%, 
100%,NA,NA 
Boberg 2006, 
(116) 
Prospective BC from 
biliary 
strictures 
61 Detection of 
malignancy/CC 
100%, 84%, 68%, 
100% 
Moff, 2006, 
(117) 
Retrospective BC from bile 
ducts 
47 Detection of 
malignancy/CC 
50%,91%,NA,NA 
Moreno Luna, 
2006 (102) 
Prospective BC from 
biliary 
strictures 
86 PSC Detection of 
malignancy/CC 
18%, 100%, 100%, 
83% 
Charatcharoen- 
witthaya,2008, 
(43) 
Prospective BC from 
biliary 
strictures 
230 Detection of 
malignancy/CC 
8 %, 100%,100%, 
89%,89% 
Levy, 2010, 
(42) 
Prospective BC from 
biliary 
strictures 
32 PSC Detection of 
malignancy/CC 
7%,100%,NA,NA 
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Halme, 2012, 
(103) 
Retrospective BC from bile 
ducts 
102 Detection of 
dysplasia/CC 
46%,88%,86%,52%  
 
Table 7.  Detection of biliary malignancy in PSC with brush cytology – metaanalysis and reviews. 
First author, 
year 
Study design 
Inter-
vention 
N Outcomes 
Results: 
Sens, Spec, 
PLR, NLR 
Comments 
Trikudanathal, 
2014 (101) 
Meta-analysis 
including 11 
studies 
(prospective 
and 
retrospective) 
 
bile duct 
brushing 
827 Diagnostic yield 
of bile duct 
brushing in 
diagnosing CC in 
PSC strictures 
43%. 97%.  
8.87, 0.56 
 
The moderate 
sensitivity in 
detecting CC, 
precludes its 
utility as a 
surveillance tool 
for early 
diagnosis of CC.  
Navaneethan, 
2014 (104) 
Meta-analysis 
including 4 
studies 
(prospective 
and 
retrospective) 
FISH  629  Diagnostic yield 
of FISH in 
diagnosing CC in 
PSC strictures 
31%. 71% 
1.19, 0.95 
 
 
FISH positivity has 
reasonable 
diagnostic 
accuracy. 
However, the 
specificity is poor.  
Meta-analysis 
including 6 
studies 
(prospective 
and 
retrospective) 
FISH 
polysom
y 
690 Diagnostic yield 
of FISH 
polysomy in 
diagnosing CC in 
PSC strictures 
51%. 93% 
6.81, 0.56 
 
FISH polysomy is 
highly specific; 
however, it has 
limited sensitivity.  
Navaneethan, 
2014 (118)  
Meta-analysis 
including 9 
studies 
(prospective 
and 
retrospective) 
Intraduc
tal 
biopsy 
730 Diagnostic yield 
of intraductal 
biopsies 
performed 
during ERCP 
48%, 99% 
18.9, 0.54 
 
Limited 
sensitivity.  
Meta-analysis 
including 9 
studies 
(prospective 
and 
retrospective) 
Brush 
cytology 
730 Diagnostic yield 
of brush 
cytology 
performed 
during ERCP 
45%, 99% 
15.7, 0,54 
 
Limited 
sensitivity.  
Meta-analysis 
including 6 
studies 
(prospective 
and 
retrospective) 
Intraduc
tal 
biopsy 
AND 
Brush 
cytology 
628 Diagnostic yield 
of both brush 
cytology and 
intraductal 
biopsies 
59%, 100% 
53.8, 0.42 
 
Both brushings 
and biopsy are 
comparable and 
have limited 
sensitivity.  
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performed 
during ERCP 
Walker, 2007 
(119) 
Systematic 
review 
MRI na Diagnosing 
cholangiocarcin
oma in primary 
sclerosing 
cholangitis 
N/A Lack of evidence 
Systematic 
review 
CT 45 Diagnosing 
cholangiocarcin
oma in primary 
sclerosing 
cholangitis 
82%, 80% 
4.10, 0.25 
 
CT provides good 
Se and Sp in 
detecting biliary 
tract carcinoma 
complicating 
primary 
sclerosing 
cholangitis 
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Endoscopic surveillance of PSC-associated IBD 
The relationship between PSC and IBD is well established (120).  The prevalence of IBD in patients 
with established PSC varies widely, but is reported at 80% in Scandinavian countries (121). The often 
asymptomatic phenotype of IBD means that prevalence data are strongly influenced by the level of 
proactive search for the disease. The typical scenario was for IBD to precede the presentation of 
PSC. However, the clinical presentation of IBD is variable, and the disease may be subclinical or 
asymptomatic for years (122) and is nowadays often diagnosed after the recognition of the liver 
disease. Notably, IBD may have been present for an unknown period of time when PSC is diagnosed.  
The increased risk of colon cancer in PSC-associated IBD, (123, 124), hence makes it crucial to 
perform a full ileocolonoscopy already at the time of PSC diagnosis in patients. As to the diagnosis of 
IBD per se, complete ileocolonoscopy is critical since rectal sparing, as well as right-sided 
involvement is frequent in these patients (40).   
Timing of screening 
22. ESGE/EASL recommend screening ileocolonoscopy at the time of PSC diagnosis (strong quality 
evidence, strong recommendation).  If IBD is documented endoscopically or histologically, annual 
surveillance colonoscopies are warranted (strong recommendation, low quality evidence). 
23. ESGE/EASL suggest that if no IBD is documented, next ileocolonoscopy should be considered at 
5 years or whenever bowel complaints suggestive of IBD occur (weak recommendation, low 
quality evidence)   
Based on initial screening subsequent surveillance can be planned. If IBD is documented, annual 
colonoscopies are warranted (6, 125), since it has been shown that PSC/IBD patients whose CRC is 
detected in a surveillance program have a significantly lower risk of CRC-related mortality as 
compared to non-surveilled patients (95). If not, repeat colonoscopy should be done with the 
occurrence of symptoms suggestive of IBD, or elevated F-calprotectin, otherwise at 3-5 years (126), 
although this recommendation lacks any scientific evidence beyond extrapolation from general IBD 
recommendations (127).    
Endoscopic modality 
24. EASL/ESGE recommend ileocolonoscopy with four-quadrant biopsies from all colonic segments 
and the terminal ileum for screening for  the presence of IBD (strong recommendation, low quality 
evidence) 
25. EASL/ESGE recommends ileocolonoscopy with dye-based chromoendoscopy with targeted 
biopsies for dysplasia surveillance of PSC-associated IBD (strong recommendation, low quality 
evidence) 
PSC-associated colitis seems to be distinctive from other IBD: Colitis is predominant in the right 
colon (128), and colon cancer is typically right-sided (129). Lack of inflammation in the rectum 
(‘rectal sparing’) is reported in some studies but less frequently observed in others  (3). Endoscopic 
surveillance of PSC-associated colitis is presumed to increase the chance of early detection of 
dysplasia or malignancy (130).  
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Screening for IBD at diagnosis of PSC is best performed by high-definition ileo-colonoscopy with four 
quadrant biopsies from all colonic segments and the terminal ileum. Biopsies should be taken at the 
index-endoscopy even without macroscopic signs of inflammation (126, 131, 132). 
In established PSC-IBD, ileocolonoscopy with dye-based chromoendoscopy (0.1% methylene blue or 
0.1% – 0.5% indigo carmine) with targeted biopsies is required for neoplasia surveillance of PSC-
associated IBD. In appropriately trained hands, in the situation of quiescent disease activity and 
adequate bowel preparation, nontargeted four-quadrant biopsies can be abandoned (133). This 
procedure is also endorsed by the ECCO (127). It should be noted that there are no studies on 
colonic neoplasia surveillance specifically in the setting of PSC-associated IBD.  
Routine use of pancolonic chromoendoscopy with targeted biopsies for neoplasia surveillance in 
patients with long-standing colitis (disease duration of >8 years) increased the proportion of patients 
found with dysplasia by a factor of 2.1–3.3 compared to standard definition video-colonoscopy. The 
pooled incremental yield of conventional chromoendoscopy with random biopsies over SD-WLE with 
random biopsies for the detection of patients with neoplasia was 7% (95%CI 3.2%–11.3%) (134). 
Benefit of conventional chromoendoscopy over WLE with latest-generation HD-WLE colonoscopes is 
unknown to date. 
Handling of polyps and colorectal dysplasia 
26. ESGE/EASL recommend endoscopic resection of any visible lesions and assessment of the 
surrounding mucosa. We recommend procto-colectomy in case of dysplasia in the surrounding 
mucosa, or when the lesion cannot be completely resected.  Otherwise, repeat colonoscopy and 
close follow-up is warranted (strong recommendation, low quality evidence) 
27. In the case of invisible lesions with HGD confirmed by two expert pathologists, procto-
colectomy should be advised (strong recommendation, low quality evidence) 
28. In the case of invisible lesions with LGD confirmed by two expert pathologists, repeat 
colonoscopy after 3 months with chromo-endoscopy is recommended (strong recommendation, 
low quality evidence). 
Colorectal cancer (CRC) risk is significantly increased in patients with co-existing IBD and PSC.  A 
meta-analysis of 11 studies concluded that patients with UC-PSC were at increased risk of developing 
CRC compared to patients with UC alone (OR: 4.09; 95%CI 2.89-5.76) (124).  A recent large 
population-based study in the Netherlands found a 9-fold increased risk of developing CRC in PSC-UC 
patients, compared to the age- and gender-matched population (SIR, 8.6; 95% CI: 3.5-17.7), and a 
10-fold increased risk, compared to UC controls (ratio of SIRs: 9.8; 95% CI: 1.9-96.6) (95). 
Most dysplasia is visible at colonoscopy (135, 136). On the other hand, invisible dysplastic lesions can 
also be diagnosed by random biopsies during surveillance. According to the IBD-Dysplasia 
Morphology Study Group (137), dysplasia is subdivided in low grade (LGD) and high grade dysplasia 
(HGD). According to the recent ECCO guidelines, a visible lesion with dysplasia should be completely 
resected endoscopically irrespective of the grade of dysplasia or the localisation relative to the 
inflamed mucosal areas (127). Subsequently, the surrounding mucosa (around the visible lesion) 
should be examined (with chromo-endoscopy-guided targeted biopsies or random biopsies if 
chromo-endoscopy not available). If endoscopic resection is incomplete or impossible, or if dysplasia 
is detected in the surrounding mucosa, total procto-colectomy is recommended. In the case of 
26 
 
invisible lesions with LGD, urgent repeat chromoendoscopy should be performed, to eventually 
identify a well-circumscribed lesion and/or perform additional random biopsies. If the presence of 
LGD is confirmed, there is no clear consensus regarding management; proctocolectomy or 
surveillance could be recommended.  Actually, two studies revealed a significant 5-year progression 
rate (33%-54%) of LGD to HGD (138, 139), whereas others showed low progression rates (140, 141). 
Finally, in the case of invisible lesions with HGD or adenocarcinoma, total procto-colectomy is 
indicated. 
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